摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methylpentan-2-yl formate | 5332-86-5

中文名称
——
中文别名
——
英文名称
4-Methylpentan-2-yl formate
英文别名
——
4-Methylpentan-2-yl formate化学式
CAS
5332-86-5
化学式
C7H14O2
mdl
——
分子量
130.18
InChiKey
VJKXDWCVZONWBR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
    申请人:SANKYO CO
    公开号:WO2003106435A1
    公开(公告)日:2003-12-24
    AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.
    新化合物具有以下式(I)的结构,其药学上可接受的盐和酯可以调节LXR功能,从而表现出优秀的抗动脉粥样硬化和抗炎活性:其中:A代表芳基或杂环芳基;R1、R2和R3相同或不同,每个代表氢、羟基、硝基、基、基、卤素、羧基、基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷基、烷磺基、烷基基、二烷基基、烷基羰基基、N-(烷基羰基)-N-(烷基)基、烷氧羰基基、N-(烷氧羰基)-N-(烷基)基、烷磺酰基、N-(烷磺酰基)-N-(烷基)基、卤代烷基磺酰基、N-(卤代烷基磺酰基)-N-(烷基)基、烷基羰基、烷氧羰基、烷基基羰基或二烷基基羰基,或R1和R2一起是亚烷二氧基;R4和R5相同或不同,每个代表氢、羟基、基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷基;X代表氢、羟基、卤素、烷氧基或卤代烷氧基;Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
  • PYRIDINE-3-CARBOXYAMIDE DERIVATIVE
    申请人:Kitamura Takahiro
    公开号:US20110237590A1
    公开(公告)日:2011-09-29
    To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.
    提供一种新型JAK3抑制剂,可用作器官移植中的预防和/或治疗剂,以及风湿性关节炎、多发性硬化、系统性红斑狼疮、干燥综合征、贝赫切特病、I型糖尿病、自身免疫性甲状腺炎、特发性血小板减少性紫癜、溃疡性结肠炎、克罗恩病、哮喘、过敏性鼻炎、特应性皮炎、接触性皮炎、荨麻疹、湿疹、牛皮癣、过敏性结膜炎、葡萄膜炎、白血病等疾病的预防和治疗。通式(1)所代表的吡啶-3-羧酰胺衍生物: 或其盐或溶剂化合物。
  • 1,2-Di(cyclic)substituted benzene compounds
    申请人:Kawahara Tetsuya
    公开号:US20050261291A1
    公开(公告)日:2005-11-24
    In one aspect, the present invention provides compounds having formula (1) or (100), a salt thereof or a hydrate of the foregoing, which compounds exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome; rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R10 represents optionally substituted cycloalkyl, etc., R20-23 represent hydrogen, alkyl, alkoxy, etc., R30-32 represent hydrogen, alkyl, oxo, etc., and R40 represents optionally substituted alkyl, etc.
    在一个方面,本发明提供具有式(1)或(100)的化合物,其盐或前述的合物,这些化合物表现出优异的细胞粘附抑制作用或细胞浸润抑制作用,并且可用作治疗或预防与白细胞粘附和浸润相关的各种炎症性疾病和自身免疫疾病的药物,例如炎症性肠病(尤其是溃疡性结肠炎或克罗恩病)、肠易激综合征;类风湿性关节炎、牛皮癣、多发性硬化、哮喘和特应性皮炎。 其中R10代表可选择地取代的环烷基等,R20-23代表氢、烷基、烷氧基等,R30-32代表氢、烷基、氧代基等,R40代表可选择地取代的烷基等。
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
    申请人:Ashikawa Masanori
    公开号:US20120004197A1
    公开(公告)日:2012-01-05
    Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, or the like; A represents N—R 11 , a sulfur atom, or an oxygen atom; R 11 represents a hydrogen atom, a C 1-6 alkyl group, or the like; B represents a C 6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
    揭示了一种具有低分子量的化合物,具有增强EPO产生和/或增强血红蛋白产生活性的化合物。具体揭示了一种EPO产生增强剂和/或血红蛋白产生增强剂,包括1-酰基-4-(取代氧基、取代基或取代基)-1,2,3,4-四氢喹啉生物,更具体地说是由通式(1)表示的四氢喹啉化合物【其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物;R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物;A表示N—R11、原子或氧原子;R11表示氢原子、C1-6烷基或类似物;B表示C6-14芳基或5-至10-成员杂环基;n表示0或1的整数】,四氢喹啉化合物的盐,或四氢喹啉化合物或其盐的溶剂化合物。
  • CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER
    申请人:Koura Minoru
    公开号:US20100280013A1
    公开(公告)日:2010-11-04
    [Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R 7 ; each X and Y independently show CH 2 , C═O, SO 2 , etc; Z shows CH or N; each R 1 , R 2 and R 7 independently show a hydrogen atom, C 1-8 alkyl group, etc.; R 3 shows C 1-8 alkyl group; R 4 shows an optionally substituted C 6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R 5 and R 6 show a hydrogen atom, etc.; L shows a C 1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)
    它是提供一种新型的LXRβ激动剂,可用作预防和/或治疗动脉粥样硬化;动脉硬化,如由糖尿病引起的动脉硬化;血脂异常;高胆固醇血症;与脂质相关的疾病;由炎性细胞因子引起的炎症性疾病;过敏性皮肤病;糖尿病;或阿尔茨海默病的预防和/或治疗剂。【解决手段】由以下一般式(I)表示的羟甲基化合物或其盐,或它们的溶剂化合物: (其中,每个V和W独立地表示N或C—R 7 ;每个X和Y独立地表示CH 2 ,C═O,SO 2 等;Z表示CH或N;每个R 1 ,R 2 和R 7 独立地表示氢原子,C 1-8 烷基基团等;R 3 表示C 1-8 烷基基团;R 4 表示可选择地取代的C 6-10 芳基基团或可选择地取代的5-至11-成员杂环基团;R 5 和R 6 表示氢原子等;L表示可选择地取代有氧基团等的C 1-8 烷基链;n表示0至2的任意整数。】
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸